|

Loratinib Clinical Trials

1 actively recruiting trial

Also known as: LORBRENA

Pipeline

Phase 2: 1

Top Sponsors

  • Guangdong Association of Clinical Trials1

Indications

  • ALK Positive Non-small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Other1 trial

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.